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ABSTRACT
The potential for commercializing a scaffold made of collagen and glycosaminoglycan to
help regenerate cirrhotic liver was analyzed and a business plan and model were created.
Using a lypholization technique, a bulk-sized and highly porous scaffold is created. It is
then inserted into the hole created by the excised liver scar tissue. By blocking
contraction of the wound and mimicking the natural extracellular matrix, the scaffold
induces regeneration of normal liver tissue. The in vivo approach is compared to several
other experimental treatments of cirrhosis found in the literature. The difficulties that
need to be addressed are explained and potential solutions are given.
A cost model was created, incorporating equipment, labor, FDA, and raw material costs.
This model was combined with information regarding the cost of current liver transplant
procedures to create a profitable business plan based on the collagen-GAG scaffolds. A
manufacturing and product sales business model was chosen due to the fairly low level of
market competition and moderate barrier to entry. The intellectual property landscape is
described and analyzed in terms of problematic existing patents and the potential for
protecting the proposed scaffolds. A timeline for future research and development was
created, with potential sources of funding during each phase. In addition to the current
embodiment of the scaffold, possible changes to the scaffold properties and composition
are proposed.
Thesis Supervisor: loannis V. Yannas
Title: Professor of Polymer Science & Engineering, Department of Mechanical
Engineering, Materials Science Engineering, and Biological Engineering
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Chapter 1. Introduction
Liver cirrhosis is a deadly condition that is very prevalent in the United States. Every
year there are over 500,000 hospital visits for chronic liver disease or cirrhosis and more
than 27,000 deaths (1). Cirrhosis occurs when healthy liver tissue is replaced by fibrous
scar tissue. The condition develops over many years as a result of chronic inflammation
due to liver disease. The diseases that can lead to cirrhosis include hepatitis B and C as
well as alcoholism. Alcoholism is responsible for about 40% of the deaths due to liver
cirrhosis each year (2). There are almost 13 million "heavy drinkers" in the United
States, of which 10 to 20 percent will develop liver cirrhosis at some point in their life (2,
3). This means that approximately 2 million people either have or will develop cirrhosis
within the next 10-15 years.
Figure 1. A healthy liver (left) compared to a cirrhotic liver (right) (4, 5).
Currently, a transplant is the only effective treatment for late stage cirrhosis. Liver
transplants are extremely costly, and the supply of donors is limited and insufficient for
the number of needy recipients. Some chemical and drug treatments are in the early
research phase, but there is no cure in the foreseeable future. An alternative approach,
taken by Dr. Yannas' lab, is to regenerate the scarred liver tissue using a tissue
regeneration scaffold. This report will analyze the current state of the liver scaffold
technology and expand on the technical hurdles still ahead before the technology can be
considered ready for commercialization. Competing technologies will be described and
briefly analyzed, with emphasis on liver transplant. The manufacturing process and costs
involved with the tissue scaffold will be detailed and the relevant FDA and intellectual
property considerations will be described. Finally, a business plan will be proposed,
including the envisioned supply chain, for turning the scaffold technology into a
successful start-up company.
Chapter 2. The Liver
2.1 Anatomy
The liver is the largest visceral organ, weighing about 1.5 kg. It is located in the right
side of the abdomen, beneath the diaphragm (6). A fibrous capsule and some peritoneum
surround the liver (7). It is traditionally broken into four lobes: left, right, caudate, and
quadrate. The right and left lobe are separated by the falciform ligament. The right lobe
is larger than the left, comprising about 60% of the liver volume. The blood supply to the
liver is composed of three major vessels. Oxygenated blood is supplied to the liver by
the hepatic artery and blood from the digestive system is supplied by the hepatic portal
vein. About 70% of the blood enters through the portal vein and the remaining 30% is
from the hepatic artery (7). Once the liver has performed its many functions, blood is
returned to the systemic circulation by the hepatic veins, which eventually empty into the
inferior vena cava (6).
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Figure 2. Anatomy of the liver (8).
2.2 Function
The liver has been associated with over 200 functions, which generally can be broken
down into three categories: metabolic regulation, hematological regulation, and bile
synthesis and secretion (6). Metabolic regulation involves regulation of levels of
carbohydrates, lipids, and amino acids in the body. All blood leaving the digestive
system flows through the liver, where excess nutrients, toxins, and metabolic wastes
are removed before the blood enters the rest of the body. If there are deficiencies,
they are corrected by releasing stored reserves or synthesis of new substances. The
liver is also where fat soluble vitamins are absorbed and stored (6).
Hematological regulation involves maintaining homeostasis in the blood. The liver is
the largest blood reservoir in the body, accounting for 25% of the cardiac output at
any given time. Phagocytic cells in the liver remove old and damaged red blood
cells, cellular debris, and pathogens. The liver cells also synthesize new plasma
proteins that help to regulate the osmotic concentration of the blood as well as
transport nutrients and blood clotting agents (6).
Bile is synthesized by the liver and stored in the gallbladder. Bile consists mostly of
water, with some ions, bilirubin (pigment), and lipids. The lipids are known as bile
salts. Bile helps to maintain acid levels during digestion and assists in lipid
breakdown (6).
2.3 Histology
The functional unit of the liver is called the lobule, and there are approximately
100,000 lobules per lobe. Lobules are hexagonal in cross section, with a central vein
at the center. At each comer of the hexagon there is a portal area, also called the
hepatic triad, which contains a branch of the hepatic portal vein, a branch of the
hepatic artery, and a bile duct. Hepatocytes, the functional cell of the liver, are
aligned in a spoke-like fashion around the central vein. Each "spoke" is only one cell
wide, and the spokes are separated by sinusoids. Sinusoids are where the blood from
the portal veins enters the lobule. As blood flows through the sinusoids it passes over
the microvilli that line the exposed surface of the hepatocytes. These microvilli give
the cell membrane a very high surface area, allowing diffusion of substances back and
forth between the cell and blood in the sinusoid. The sinusoid is lined by endothelial
and Kupffer cells. Endothelial cells line all blood vessels and Kupffer cells are
phagocytes that engulf pathogens, cell debris, and damaged red blood cells. The
Kupffer cells also retain heavy metals like tin and mercury. To allow large
substances to pass through, the sinusoids have openings called fenestrae. Once the
blood has passed by the hepatocytes it empties into the central vein, which eventually
connects back to the hepatic veins and then the inferior vena cava (6).
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Figure 3. Schematic diagram of a liver lobule (9).
Chapter 3. Current Treatment
As mentioned previously, the only truly effective treatment for liver cirrhosis is a
liver transplant. Liver transplants can be taken from recently deceased or living
donors. Living donors can have one of the right or left lobes removed; typically the
left is taken for a child and the right for an adult (10). Approximately 6,500
transplants are performed each year, but about 17,000 people remain on the waiting
list at the year's end. The surgery can take between six and twelve hours, and
requires a hospital stay of up to three weeks following surgery (2). The hospital stay
could be shorter, from five to ten days, but frequent assessments have to be done for
up to a month after the surgery. For this reason, it is recommended patients arrange
for living accommodations near the hospital (10). Aside from having to take
immunosuppressant drugs for the rest of their life, patients can return to a normal
lifestyle after about six months. The five-year survival rate is about 75% (2).
Due to the time consuming donor-recipient matching process, organ procurement,
complexity of the surgery, and extensive recovery time, liver transplants are
extremely expensive. The table below breaks down the cost of each aspect of the
transplant.
Evaluation Procurement Hospital Physician Follow- IS Drugs Total
up (first year)
$25,900 $59,100 $248,100 $66,900 $88,500 $31,100 $519,600
+
-$360,000 $879,600
For 20 After 20
additional years
years
Table 1. Cost breakdown of each part of the transplant process (11)
The cost of the transplant and the associated fees and drugs for the first year is
$519,600 (11). However, some of the immunosuppressant drugs must be taken for
the rest of the patient's life. If a patient were to live 20 more years after the surgery,
this would add up to an additional $360,000 (12), for a total cost of almost $880,000.
Medical insurance coverage varies widely by policy, patient, and hospital, so a
definitive breakdown of who will pay what costs is impossible to know. It is
estimated, however, that private insurance will typically pay about 80% of the
transplant costs. Patients who qualify for Medicare will have most of the bill paid,
minus some deductibles and physician fees (12).
Chapter 4. Competing Technologies
Although a liver transplant is currently the only treatment used, combating cirrhosis is
an active research field. Most approaches rely on proteins or peptides to either
directly reduce the amount of fibrous scar tissue or to affect the processes that govern
its formation and regression. An example of the former is the injection of collagenase
directly into the portal vein, a study done by Jin et al. (13). Collagenase is an enzyme
that breaks down collagen, the primary component of scar tissue. In the study,
bacterial collagenase was delivered directly to the portal vein of CCl4-induced
cirrhotic livers in rabbits via a catheter.
The experiment consisted of four groups: a control group, a group that received CC14
for 12 weeks and collagenase for weeks 7-12, a group that received CC14 for 12
weeks followed by 12 weeks of collagenase, and finally a group given CC14 for 12
weeks followed by saline for 12 weeks. This allowed for analysis of the effect of
collagenase with the cirrhosis stimulant still there (Hepatitis), and without it (a former
alcoholic). The rabbits were given 6 mg of collagenase twice a week. The results of
the study showed that simultaneous infusion of CC14 and collagenase resulted in less
collagen formation than CC14 alone, although still above the control levels.
Collagen content was determined using a hydroxyproline assay. The group that
received collagenase for 12 weeks after a full 12 weeks of CC14 showed a drastic
reduction in liver fibrosus and was almost back to normal according to the histology.
However, the group receiving only saline injections also showed a large reduction in
fibrosus, although not as completely. The hydroxyproline levels of the group III
rabbits returned to almost control levels, while the group IV rabbits receiving saline
injections was still significantly above the control (13).
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Figure 5. Hydroxyproline content after 12 weeks of CCl4 and 12 weeks of collagenase or saline (13).
Overall, the results showed that portal collagenase injections can help slow cirrhosis
development while given concurrently with a cirrhosis causing stimulant and can also
cause regression of fibrosus when the stimulant is removed. While the study is
encouraging, there are some notable risks and questions that remain. The first is that
during the study, 46% of the rabbits died prematurely due to surgical complications.
It is not believed that this had any effect on the results or that the collagenase
treatment had anything to do with the high death rate; however it shows the potential
for complications that may occur if the approach was translated to humans. The
second concern is that while the collagenase did significantly accelerate the
regression of fibrosus, the rabbits receiving saline injections also showed marked
signs of regression. It could be hard to distinguish the effect of collagenase versus the
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removal of the cirrhotic stimulant. Lastly, although tests that were done on the blood,
kidneys, heart, and brain showed no adverse effects from the collagenase treatment, it
is still likely that there could be some sort of long-term side effects of the treatment in
humans. The collagenase injections were only done over a 12 week period, not long
enough to ascertain any chronic toxicity or other long-term implications.
A second approach, published in 2002 by Vinokurov et al., was to use adrenoceptor
agonists to reduce the effects of TGF-P in formation of liver cirrhosis. The specific
adrenoceptor agonist used was dobutamine. The motivation for suppressing the effect
of TGF- P is that it stimulates the formation of connective tissue and inhibits
hepatocyte proliferation (14). Cirrhosis was induced in mice using CC14,
administered twice a week for 30-60 days. The hepatocytes from the treated mice
were then cultured with various combinations of EGF and dobutamine to determine
their proliferative activity. The cells cultured with dobutamine showed a significantly
higher proliferative activity than those with just EGF. The proliferative activity was
maximized with a dobutamine concentration of 8 jtg/ml (14). In in vivo tests,
treatment with dobutamine 24 hours after a partial hepatectomy (HPE) showed an
increase in proliferative activity compared to PHE alone. However, when combined
with CCl4, the proliferative activity was reduced to levels slightly above the control
(14).
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Figure 6. Proliferative activity of hepatocytes after culturing with dobutamine for 8, 16, and 24 hours
(14).
4Figure 7. Proliferative activity of hepatocytes after 8, 16, and 24 hours (white, dark, shaded), when
preincubated in EGF (2-4) or dobutamine (5) (14).
While this study was interesting, the results need to be examined critically. First, the
initial studies were done in vitro, and proliferative activity may or may not be the
same in culture as it is in the body. Second, the in vivo tests are done mostly with
PHE, but the test with CC14 and dobutamine does not involve a PHE, making the
results difficult to compare. Also, since the liver is able to partially regenerate on its
own, conducting a PHE can make it difficult to separate the effects of the dobutamine
from the natural proliferation activity of the body.
Another approach, published recently by Buck and Chojkier, is to block ribosomal S-
6 kinase (RSK) activation using an inhibitory peptide (15). It was shown that
activation of RSK caused phosphorylation of protein C/EBPI on a gene in hepatic
stellate cells (HSC) that leads to synthesis of excessive extracellular matrix (ECM).
However, when a transgene, C/EBPP-Ala217, replaced the normal version, fibrosis
was not observed. The same result was achieved by treating the mice with a cell
permeant RSK inhibitory peptide. When cirrhosis was induced using CC14 for 8
weeks, followed by treatment with the peptide for 4-8 weeks, apoptosis (cell death) of
the HSC and regression of fibrosis was observed (15). A similar pathway to liver
fibrosis exists in humans, leading the researchers to believe that this approach may be
applicable to people. This is certainly another promising study in the fight against
liver cirrhosis, but again must be examined critically. Currently gene therapy is very
limited and experimental in humans, and getting FDA approval is extremely difficult.
This means that the cell permeant peptide would likely be the first form of this
treatment to be viable in humans. Once again the treatment requires repeated dosing
and the effects on the rest of the body are unknown as well as the appropriate delivery
method.
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Figure 8. Mice with Transgene show 2.5X reduction in fibrosis (15).
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Figure 9. Mice treated with RSK inhibitory peptide show significant decrease in collagen (15)
Chapter 5. Proposed Technology
5.1 Overview
The technology proposed to produce liver regeneration is a collagen and
glycosaminoglycan (GAG) scaffold. It is created by a lypholization procedure and is
highly porous. The scaffold will be placed in the wound of the surgically excised
scarred liver tissue. Due to certain size constraints, which will be described later,
multiple scaffolds may be placed to achieve the desired total volume. The scaffold
will then induce regeneration based on principles described by Dr. Yannas and due to
the unique properties of the scaffold.
5.2 Materials
The primary component of the scaffold is collagen. There are many types of collagen
in the collagen family, but the proposed scaffold uses type I. Collagen is the primary
tensile load bearing structure in the extracellular matrix but also serves functions in
tissue scaffolding, cell adhesion, cell migration, angiogenesis, and more (16).
Collagen is composed of a triple helix of polypeptide (a) chains. The chains are
arranged in a right handed super helix and each chain has a repeating amino acid
sequence of Gly-X-Y, where Gly is glycyl and X and Y are often proline and
hydroxyproline. The three chains are held together by hydrogen bonds (16). Each
chain contains 1050 amino acid sequences and is 300 nm long and 1.5 nm in diameter
(17). Many of the collagen triple helix molecules pack together side by side to create
collagen fibrils. These fibrils are 50-200 nm in diameter and are several micrometers
long. The collagen molecules come together in a staggered manner, with a
periodicity of 67 nm. This results in a "banded" structure (17).
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Figure 10. The structure of collagen molecules, fibrils, and fibers (18)
Collagen is resistant to most proteases (enzymes that break down proteins), but is
susceptible to matrix metalloproteinases (MMPs), cysteine proteinases, and
serine proteinases (16). The liver is only about 0.5% collagen by weight (wet), and most
of the collagen is type I and III. In cirrhotic liver the amount increases about tenfold to
5% by weight and type I becomes more predominant (19).
The second component of the scaffold is glycosaminoglycan, or GAG.
Glycosaminoglycans are polysaccharides with a disaccharide repeat sequence (20). One
of the repeat units is an amino sugar and the other is usually an uronic acid. There are
many types of GAG, with some of the most common being chondroitin sulfate, heparan
sulfate, keratan sulfate, and hyaluronic acid. GAG molecules are often covalently
attached to a core protein to create a macromolecule called a proteoglycan. GAGs help to
localize proteins and enzymes at their point of function with cells and the ECM (20).
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Figure 11. The chemical structure of chondroitin sulfate, one of the common GAGs (20)
5.3 Scaffold Properties
The tissue regeneration scaffolds created by Dr. Yannas' group are highly porous, with a
pore volume fraction of over 99%. The scaffold is 0.5 wt% collagen type I and 0.05 wt%
chondroitin 6-sulfate. The pore size can be tailored by the freeze-drying process, but is
typically from 90-150 gLm (21). The pores are equiaxed and fairly uniform in size. The
pores are also interconnected throughout the scaffold, allowing cell and nutrient
migration. The scaffolds currently being used in mice studies are cylindrical in shape
with a radius of 1.5 mm and a height of 5 mm. This gives a volume of 35.3 mm3 , or
0.0353 cm3. Using the liver to body weight ratios of mice and rats (5.8%), their average
body weights (20 grams and 300 grams), and an empirical equation for rat liver volume
for a given liver weight (eq. 1) an average mouse liver volume of 1.09 cm 3 was reached
(22, 23).
Lv = 0.892 x Lw + 0.8 (1)
Using these values, the current studies are being done with a scaffold that replaces
approximately 3.2% of the mouse liver volume. An average human liver (men and
women combined) is approximately 1470 cm 3 (24). In order to duplicate the proportional
size and shape of the mouse scaffold, a human scaffold would therefore have a radius of
3.3 cm and a height of 5.5 cm and a total volume of 47 cm3 . To control the degradation
rate of the scaffold, the molecular weight between crosslinks, Mc, can be altered. A
higher value of Me results in faster degradation due to a lower crosslink density. The
scaffold proposed likely will have an Me of 5-15 kDa and should degrade in the body
within about 40 days (25).
Figure 12. A SEM image of the collagen-GAG scaffold showing large, equiaxed pores (25).
The mechanical properties of the scaffold are also important. The Young's modulus
of a scaffold has been shown to affect cell adhesion, growth, and differentiation (26).
Cell migration speed is also influenced by substrate stiffness, showing a biphasic
relationship with a maximum speed at intermediate stiffness. The elastic modulus of
the collagen-GAG scaffolds is approximately 2,000 Pa while hydrated (26). The
individual struts were shown to have a modulus of about 5.3 MPa while hydrated
(26). The mechanical properties of the scaffolds as a whole do not vary with pore
size, which is consistent with cellular solids theory that is used to model them (26).
Increasing the crosslink density causes the strut modulus to increase. This can create
large changes in the overall scaffold modulus, up to an order of magnitude (26).
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Figure 13. Stress-strain relationship of a hydrated collagen-GAG scaffold in uniaxial tension (26).
5.4 Scaffold Manufacturing
The collagen-GAG scaffolds are created using a lypholization technique, also called
freeze-drying, where the collagen-GAG slurry is frozen and then put under vacuum to
cause the ice to change to gas. When the ice crystals nucleate throughout the
suspension they push the collagen and GAG aside, creating the 3D network of
interconnected pores. When the ice undergoes sublimation, the water vapor can exit
the scaffold without disrupting the newly formed pore structure.
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Figure 14. Phase diagram of water, showing solid to ice transition at low temperature and pressure
(27).
First, microfibrillar type I collagen (typically from bovine tendon or rat tail) and
chondroitin 6-sulfate (typically from shark cartilage) are blended in 0.05 M acetic
acid of pH 3.2 at 15,000 rpm. The suspension is maintained at 4°C during mixing to
prevent denaturation of the collagen. To achieve the afore mentioned weight percents
of collagen and GAG, 3.6 grams of collagen and 0.36 grams of chondroitin 6-sulfate
are used per 720 ml of acetic acid. To make one human-size scaffold, that equals 235
mg of collagen and 23.5 mg of GAG. After mixing the suspension, it is degassed
under 50 mTorr vacuum for one hour to remove air bubbles (21). After degassing,
the suspension is placed in stainless steel pans measuring 10.25 x 10.75 x 5.5 cm.
Larger pans can be used, but it was found that smaller pans create a more uniform and
equiaxed pore structure due to higher stiffness and better contact with the freeze-dryer
shelf (21).
The pans are placed in a freeze dryer that begins at room temperature. The
temperature of the shelves is then lowered at a constant cooling rate until the final
temperature of -400 C is reached. The cooling rate can be adjusted to achieve a range
of pore sizes. As the cooling rate increases, the pore size decreases due to increased
nucleation and lowered growth of the ice crystals formed in the suspension (21).
Smaller pore sizes have been shown to increase cell adhesion due to the increase in
ligand density (28). Ligands are adhesion molecules that are recognized by cell
membrane receptors (integrins) and allow cells to adhere and migrate across a
surface. The pore size of the structure cannot be too small, however, because below a
certain size cells and diffusing nutrients will not be able to easily fit through the
openings in the scaffold (25). For this reason, an intermediate pore size, and
therefore cooling rate, is needed. To achieve this, the cooling time should be between
60-90 minutes to reach -400 C. After the final temperature is reached, it is held for 60
additional minutes to allow for complete phase transition to occur. After cooling is
completed, the suspension is sublimated under less than 100 mTorr for 17 hours at
00 C to remove the vapor.
Following the freeze-drying process, the scaffolds are dehydrothermally crosslinked
and sterilized using a vacuum oven. The scaffolds are placed in the oven at a
temperature of 1050 C for 24 hours at a vacuum of 50 mTorr. The process introduces
covalent crosslinks between the polypeptide chains of the collagen without denaturing
it into gelatin (21).
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Figure 15a. Schematic of the manufacturing process with examples of the necessary equipment (29,
30, 31).
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Figure 15b. Diagram of the scaffold manufacturing process (32).
Chapter 6. Organ Regeneration
Organ replacement has been addressed from multiple angles throughout medical
history. The five approaches currently used or being researched are transplants,
autografts, permanent implants, in vitro synthesis, and in vivo synthesis (25). As
already mentioned, transplants are extremely expensive and there are not enough
donors to satisfy the need. Autografts and permanent implants cannot be used for
procedures as complicated as a liver replacement. That leaves in vitro and in vivo
synthesis as the two possible approaches to replacing a failed liver. In vitro synthesis
of a 3D organ is very difficult because it is not yet possible to create a tissue with a
fully developed vasculature. Most in vitro tissues rely on diffusion of nutrients from
culture medium and are therefore restricted to very thin cross sections for sustained
life. In vitro synthesis is also difficult because there is not a way to truly recreate the
body environment in the lab. It is possible to include some growth factors, control
the pH level, and even simulate the extracellular matrix to a fairly high degree, but it
is simply not possible to exactly copy the in vivo environment. This makes it
extremely difficult to create an organ that will be physically and histologically
identical to the natural tissue. Even if it were possible, there is a chance that by
implanting it into the body, the change in environment would destroy it or alter its
function.
It would seem, then, that in vivo synthesis is the best approach to replace a failed
organ. The goal is to only implant what needs to be implanted and let the body
supply the rest. It has been shown in the skin and conjunctiva that it is possible to
achieve regeneration with only a scaffold similar to the one proposed here (25).
To be suitable as a regeneration template, a scaffold must meet four structural
characteristics. First, it must have the appropriate chemical composition. This is
necessary to ensure that the right ligands exist for the host cells to adhere to and
migrate on the scaffold (25). Collagen and GAG are both naturally occurring in the
body, and specifically the liver, and therefore the scaffold composition should be
acceptable. Second, the scaffold must contain the right pore structure and size. High
pore volume fraction and smaller pore sizes both increase the ligand density in the
scaffold because they both increase surface area (25). The collagen-GAG scaffold
proposed has an extremely high pore volume fraction (>99%) and the ligand density
for the pore sizes tested have shown to provide good cell adhesion (28).
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Figure 16. Effect of pore size on cell adhesion (28).
Third, the scaffold must have the correct pore orientation for the application. The
orientation of the pores can dictate the cell migration and synthesis direction,
therefore affecting the regeneration process (25). The liver is a bulk tissue with many
small units called lobules that are roughly hexagonal in shape. An equiaxed pore
structure should fit well with this morphology because there is no preferred axis of
tissue growth. The shape of the pores does not precisely mirror the natural ECM, but
enzymes will be able to remodel as necessary to attain the correct structure. Lastly,
the macromolecular structure must be appropriate. This affects the degradation rate
of the scaffold. It has been found that tissue regeneration occurs best when tissue
growth occurs at the same rate as scaffold degradation (25). The current embodiment
of the scaffold is meant to degrade in approximately 30 days. This is accomplished
with a molecular weight between crosslinks, Me, of 5-15 kDa. To increase the time
of degradation, the M, can be decreased to give a higher density of crosslinks and
therefore a more resilient scaffold. As will be discussed later, the time to degradation
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for this application likely will need to be on the order of 40 days, so an Mc of around
5 kDa may be the solution.
Figure 17. Axially aligned pore structure (top) versus equiaxed (bottom) (25).
In addition to having the above characteristics, the scaffold must be able to prevent
the natural wound healing response from occurring. In humans, the ability to
regenerate most tissues ends during the late stages of fetal development. Some
tissues continue to regenerate naturally, such as bone and the epidermis of the skin,
but others heal by contraction and scar formation. It is not completely understood
why some tissues are able to regenerate and others aren't, but it is known that in order
to induce regeneration, it is necessary to block the contraction that occurs in non-
regenerating tissues (25). If contraction is blocked then scar tissue does not form, and
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the wound is sometimes able to heal by regeneration. Blocking contraction is
therefore necessary, but is not sufficient to achieve regeneration.
Contraction is blocked by reducing the number of contractile cells in the wound and
by randomly orienting the contractile cells that remain. The first task is accomplished
due to the unique characteristics of collagen precipitated using GAG from an acidic
solution. When the collagen fibrils form under these conditions, they do not exhibit
the characteristic "banding" structure nearly as much as seen in native collagen. The
un-banded collagen retains its triple helical structure, however, so it is not turned to
gelatin (25). The banding structure in collagen attracts platelet cells during blood clot
formation following wound creation. With significantly less banding, there is
severely reduced clotting and the cytokine TGB-P that is normally released during
clotting is not as prevalent in the wound. TGB-P is known to encourage normal cells
to turn into contractile cells, so with less of it in the wound there are less contractile
cells as well (25).
The second task, randomly orienting the contractile cells that do arrive in the wound,
is accomplished by the randomly oriented pore structure (Figure 10). When the
contractile cells migrate into the scaffold they become oriented in the direction of the
pore strut on which they are attached. When they contract as a whole, the effects are
mostly cancelled due to the opposing alignments of the cells. Cells also synthesize
matrix in the direction of their cell alignment. This means that instead of highly
oriented scar tissue, as seen in most wounds, the synthesized ECM will be fairly
isotropic as it was before the wound.
Figure 18. Scar formation in a preferred direction without a scaffold (top) and randomly oriented with
a scaffold (bottom) (25).
Chapter 7. Technical Hurdles
At this point, the collagen-GAG scaffold has been shown to block contraction in a
surgically created wound in a healthy mouse liver. The next step is to show that the
same can be accomplished in a cirrhotic mouse liver, likely by giving the mice CC14.
The scaffold has had success in the past with blocking contraction in scarred tissue,
although not in the liver, so it is reasonable to expect that it will be able to do it on
this small scale. The biggest obstacle, however, is the massive increase in size from a
mouse to a human liver. As mentioned above, to replace 3.2% of the liver in a mouse
requires a scaffold that has a volume of 0.0353 cm3, but to replace the same relative
amount of a human liver requires a volume of 47 cm3. That is an increase of
approximately 1330X.
The main problem with such a drastic increase in size is that oxygen and nutrient
transport to the cells occurs by diffusion. The maximum thickness of a tissue is
therefore only a few hundred gtm to as low as 20-30 gLm, depending on which study
you look at (33, 34, 35). Even if cells do survive and proliferate into the scaffold, if
the time for oxygen to reach them is too long then a hypoxic environment forms (36).
In a hypoxic environment, cells convert glucose to lactic acid and necrosis starts to
occur (36).
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Figure 19. Schematic representation of the relationship between time and thickness of a scaffold in
determining whether cells will proliferate or start to die (36).
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In order to have tissue regeneration in a scaffold with a thickness of a few cm,
extensive vasculature must be present within the scaffold before hepatocytes will be
able to survive. It is therefore imperative that angiogenesis be as rapid and robust as
possible. Endothelial cells migrate at about 0.4 mm/day (37). This means it will take
approximately 40 days to reach the most central parts of the proposed scaffold, with a
radius of 1.65 cm. This time frame may be too long and it may be necessary to
develop ways to speed up the process.
One way to improve the blood vessel ingrowth may be to incorporate Vascular
Endothelial Growth Factor (VEGF) into the scaffold using PLGA microspheres. In a
study done by Kedem et al., a dramatic increase in density and size of capillaries was
shown in a scaffold placed on the liver surface in rats by addition of VEGF
microspheres (38). At the end of a two week period, the scaffold containing VEGF
had an average capillary density of 220/mm 2 compared to 139/mm 2 for the control
scaffold (38).
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Figure 20. The difference in capillary density between scaffolds with and without VEGF (38).
Assuming a square array of capillaries, there would be a capillary every 67.4 pm for
the scaffold with the VEGF and every 84.8 gpm for the control. This translates to a
maximum diffusion distance, for a cell located directly in the center of the square
array, of 47.7 pm with VEGF and 60.0 ptm without. The area of the scaffold
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consumed by capillaries was not significantly different at 1, 7, and 14 days, so it does
not appear that VEGF causes the capillaries to grow faster, just in greater numbers.
The size distribution of the capillaries was significantly different, with the VEGF
scaffolds having almost 40% of the capillaries with a diameter of over 16 pm as
opposed to only 10% in the scaffolds without VEGF. The capillaries in the VEGF
scaffold also stained positive for smooth muscle actin (SMA), which is an indicator
that the vessels are mature and will not regress (38).
Figure 21. Histology of newly formed capillary in VEGF scaffold with arrow pointing to SMA around
a large capillary (38).
The microspheres are created using a modified solvent evaporation method based on
a double emulsion (39). First, 50 tl of aqueous solution containing 20 mg of BSA
and 3.75 gLg of human recombinant VEGF are mixed with 200 mg of PLGA dissolved
in 0.5 ml of methylene chloride (38, 39). This mixture is then sonicated to form an
initial emulsion. Then, 1 ml of 1% (w/v) aqueous PVA is added to further emulsify
the mixture. The double emulsion is then poured into 50 ml of 0.1% (w/w) PVA
solution and then stirred for 5 minutes before adding 50 ml of 0.1% (w/w) PVA
containing 10% (v/v) 2-propanol (39). The solution is then stirred for 30 minutes and
the microspheres are removed by centrifugation and then freeze dried. The
microspheres are typically between 65-70 jim in diameter. When used in a smaller
scaffold by Kedem et al., the microspheres were incorporated at a ratio of 40 mg of
microspheres per 0.16 cm 3 of scaffold (38, 39). The release rate was approximately
8-10 ng/day, which lasted for more than two weeks (38).
Figure 22. Microspheres as fabricated (A) and after 5 (B), 14 (C), and 30 (D) days in phosphate buffer
at 370 C and pH 7.4 (39)
In addition to adding growth factors, such as VEGF, to increase vascularization, other
approaches can be taken to improve nutrient diffusion and transport. Increasing the
pore size has been shown to increase the permeability of tissue engineering scaffolds
(40). Scaffold permeability is a function of porosity, pore size and distribution, pore
interconnectivity, fenestration size and distribution, and pore orientation (40). It can
be quantified using the fluid mobility, K, which is defined as the permeability divided
by the viscosity of the fluid.
k
K= - (2)
For the collagen-GAG scaffolds, the fluid mobility is on the order of 10-10 m4/Ns,
which compares favorably to some natural tissues, such as cartilage at 10-5 m4/Ns,
and is on par with some other synthetic scaffolds made of PLA and PGA. The fluid
mobility can be almost doubled by increasing the pore size from 96 to 150 iim (40).
This would likely increase the critical distance needed between capillaries and may
allow for non-VEGF scaffolds to succeed.
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Figure 23. The effect of pore size on fluid mobility for collagen-GAG scaffolds (40).
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Table 2. Permeabilities and fluid mobilities for various synthetic and natural tissue engineering
scaffolds (40).
As mentioned in Chapter 6, however, increasing the pore size can have an adverse
affect on cell adhesion. The nutrient transport and vascularization problem is likely
to be the most significant though, so sacrificing some cell adhesion may be necessary
to achieve a viable scaffold.
If adding growth factors or altering pore size is not sufficient to get the necessary
nutrient transport, a more extreme approach may be necessary. Recently, in an effort
to solve the vascularization problem, studies have been done where arteriovenous (A-
V) loops are inserted into a scaffold to encourage vessel growth (36). Briefly, vein
grafts are used to re-route existing arteries into a chamber containing a scaffold (41).
This allows vessel formation to occur from the inside, in addition to from the surface
of the scaffold.
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Figure 24. Schematic of an A-V loop used without a scaffold (41).
Incorporating the A-V loop strategy into the overall liver regeneration procedure
would likely not affect the scaffold fabrication. Instead, it would probably be up to
the surgeon performing the operation to cut the scaffolds in half, creating an upper
and lower portion, and then re-route an artery or other existing blood vessel to form a
loop that could be placed between the two halves. This may prove difficult, and
could be unnecessary if the VEGF and pore size are effective. However, since
portions of the liver are already being removed during surgery, there is likely a
significant supply of grafting material that could be taken from the excised tissue.
This would eliminate the need to find a donor site elsewhere in the body, reducing the
risk of complications.
Chapter 8. FDA Considerations
All medical devices sold or used in the United States must be approved by the U.S.
Food and Drug Administration (FDA). Devices are divided into three types: I, II, and
III. Type I devices are the simplest and have the least possible health risk. Examples
are bandages, surgical gloves, and simple hand tools. Type I devices must meet
"General Controls," which include registering the device and its manufacturers,
meeting Good Manufacturing Processes (GMP), labeling, and a premarket
notification [510(k)] (42). The 510(k) is necessary to show that the product is
substantially equivalent to a previously approved device in terms of the intended use,
materials used, and safety and effectiveness.
Type II devices are subject to "General Controls" and "Special Controls," which
include special labeling requirements, mandatory performance standards, and
postmarket surveillance (42). They also require a 510(k). These devices are more
complicated and pose a higher health risk. Examples include infusion pumps and
tubes to reconnect damaged nerves. The highest risk, and therefore most regulated
devices are Type III, and require a premarket approval (PMA). A PMA is necessary
to prove or demonstrate safety and effectiveness of the new device, which is done
through preclinical and clinical studies (42). The preclinical trials, using in vitro tests
and animal studies, must show that the materials, chemical composition, and
manufacturing process are biocompatible and safe. Biocompatibility tests include
toxicity, irritation, implantation, and genotoxicity. Clinical trials in human patients
must also be done for Type III devices to show that the device is not only safe, but
effective. These trials can range from tens to hundreds of patients and generally
include at least one control group for comparison.
Because there are no liver regeneration scaffolds on the market, or any similar
products with the same function or intended use, the collagen-GAG scaffold would
almost definitely receive Type III classification. From a device company's
standpoint, Type III is the worst possible type due to the expense and time of
conducting the extensive tests and trials. The materials and chemical composition
analysis have either been done already or could be completed fairly easily in the MIT
labs, but the biocompatibility tests and clinical trials would be difficult or nearly
impossible to conduct due to the extra equipment, labor, and time restrictions
required. There are contract research organizations (CRO) that will conduct or
organize these studies in their own labs. For a small startup company with very few
employees and limited lab space/equipment, having a CRO do the preclinical and
clinical trials is likely the easiest and most sensible route. The costs of these tests will
be discussed in the cost model section.
It is important to note that the above information is for medical devices, which are
defined as:
"an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar
or related article, including a component part, or accessory which is:
- recognized in the official National Formulary, or the United States Pharmacopoeia, or any
supplement to them,
- intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment,
or prevention of disease, in man or other animals, or
- intended to affect the structure or any function of the body of man or other animals, and which does
not achieve any of it's primary intended purposes through chemical action within or on the body
of man or other animals and which is not dependent upon being metabolized for the achievement
of any of its primary intended purposes (42)."
The critical part of the definition, which is in bold above, is that devices do not rely
on chemical action or being metabolized by the body to perform their intended
purpose. This is an accurate description of the collagen-GAG scaffold in its current
form. However, if VEGF microspheres are added to the scaffold then the
classification could become fuzzy. The inclusion of VEGF could cause the device to
be classified as a drug or biologic, which can have different (and typically more
extensive) testing procedures and timelines. It is possible that the collagen-GAG
scaffold would still be classified as a device, evidenced by the approval of the
InFUSE Bone Graft/LT-CAGE Lumbar Tapered Fusion Device by Medtronic (43).
Chapter 9. Intellectual Property
At a minimum, any new device must not infringe on any existing patents without
some sort of licensing agreement. Preferably, a new product would be patentable,
therefore allowing the inventor/company to exclude others from producing it or
selling the idea. A background patent search was done to assess the relevant IP in the
liver regeneration scaffold field. There are a myriad of patents for scaffolds involving
bone and cartilage repair, some of which include lengthy background sections that
"teach" the use of collagen and polysaccharides (GAG) in scaffolds to induce
regeneration. The extent to which these patents truly teach the collagen-GAG
scaffold discussed here is very debatable. The body and the claims of the patents
focus almost entirely on bone or soft tissue (cartilage, ligament, etc.) regeneration and
make only fleeting references to visceral organs in the form of tables of possible
materials and treatment sites. A list of the relevant patents, starting with the most
recent, and a summary of the IP outlook is provided below.
1. US 7,241,316 - Devices and Methods for Treating Defects in the Tissue of a
Living Being (bone oriented)
2. US 7,105,580 - Porous Structures Useful for Growing Living Tissue, and
Methods of Manufacture (manufacturing methods)
3. US 6,969,523 Collagen/Glycosaminoglycan Matrix Stable to Sterilizing by E-
Beam Radiation (manufacturing methods)
4. US 6,962,716 - Compositions and Methods for Biodegradable Microspheres as
Carriers of Bioactive Substances (new microsphere method)
5. US 5,330,768 - Controlled Drug Delivery Using Polymer/Pluronic Blends
(original microsphere patent)
6. US 4,947,840 - Biodegradable Templates for the Regeneration of Tissues
(original Yannas patent)
The first patent, US 7,241,316, has an extensive background section that reviews the
recent prior art for all types of tissue engineering scaffolds. The summary of the
invention describes a synthetic tissue substitute material that can be composed of
polymer, ceramic, or metals. It will partially or fully resorb in the body. It may
contain a depot of material to assist in the in-growth of cells, possibly cytokines or
drugs. All of these are fairly generic to the tissue engineering scaffold field, and do
not teach the specifics of the proposed scaffold. While specifying potential materials
to be used, collagen, polysaccharides, PLGA, and VEGF are all included in very long
tables as examples. Lypholization of collagen implants is also mentioned in the body,
but this is a very old and common manufacturing method that is not patentable
anyway. The use of microspheres is described in the body, but the specific use of the
double emulsion process as well as the VEGF is not included. The liver is listed as a
potential target tissue, however it is only present in a long list and there is no detailed
mention of it in the body. Pore size and volume fraction are described as 25-1000 gm
and over 50%. The values of the proposed liver scaffold are within these ranges, but
the pore size range is extremely large and the proposed porosity is much more
specific than what is cited. The claims of the patent do not pose any difficulties for
the liver regeneration scaffold because they specifically mention the regeneration or
repair of bone tissue.
The second patent, US 7,105,580, describes a scaffold that is fairly similar to the
collagen-GAG scaffold proposed, and also its manufacture. The main difference,
however, is that the patented scaffold includes amino acids in the lypholization
mixture. The claims also do not mention the liver or overall porosity. There are
claims that describe the pore size as 1-100 or 1-300 jgm, which do overlap with the
proposed scaffold. The patent also does not specify a method by which it can induce
regeneration. Overall, the patent does not pose a significant challenge to the
production of the collagen-GAG scaffold. It may, in fact, give hope that the
manufacturing method of the liver scaffold could be patentable if small twists are
added to distinguish it from existing lypholization techniques.
The third patent, US 6,969,523, is assigned to Integra LifeSciences, who produces a
scaffold very similar to the proposed scaffold for skin defects. The product is based
off of Prof. Yannas' research on wound healing and treatment. The difference,
however, is in the application and the scaffold geometry. Also, the Integra patent
includes an extra component, a layer of silicone that covers one surface to prevent
loss of moisture. The claims do not specify a tissue type, but the silicone layer makes
the scaffold only applicable to surface wounds. The patent claims include the
lypholization technique used for the proposed liver scaffold, but specify a different
crosslinking and sterilization method. Overall, this patent should not preclude the
liver scaffold from being manufactured, since there are clear differences in the
composition and size/shape, but may cause some problems for attaining patents on
the new scaffold. This is due to the potential for the USPTO to say that the use of the
very similar scaffold in a new application and with a different size/geometry is
"obvious" and therefore not patentable.
The fourth patent, US 6,962,716, details the production of microspheres that can
release bioactive substances. The use of VEGF is specifically mentioned and
described in some detail, although not explicitly for the liver. The claims of the
patent, however, only specify a single emulsion process. The rest of the processes
and components are very similar to the double emulsion process described in chapter
7. The claims include being biodegradable, including VEGF, emulsifying with PVA,
and retrieving the microspheres with centrifugation. This patent only poses a
difficulty if 1) VEGF microspheres are used in the scaffold and 2) if it is necessary to
work around the fifth patent, which will be discussed next.
The fifth patent, US 5,330,768, is the patent for the exact double emulsion
microsphere synthesis process that is described in chapter 7. The good news,
however, is that it was filed in 1991, meaning it only has three years left of
exclusivity. As the proposed timeline shows in the business model chapter, there will
likely not yet be a commercial product in three years. This means that if VEGF
microspheres are necessary there are a few options. The first is to work around the
patented double emulsion process in a way that still yields effective microspheres.
This is where the fourth patent, above, comes into play. The likelihood of finding a
way other than the single emulsion process described in that patent is probably fairly
slim and the pursuit of finding it would sidetrack the entire focus of the liver scaffold.
The second option is to license the technology for the next three years while waiting
for the protection to expire. Since it is so close to expiring, the inventors may be
willing to license the patent for fairly cheap since they won't be able to profit from it
at all for much longer. Also, the inventors are from MIT, who is the assignee, so
working out a deal would likely be quite straightforward. The last option is to just
wait it out and let the protection expire in 2011. The reality is that lab tests with the
scaffold alone will probably still be ongoing in 2-3 years, so waiting may be the most
practical approach.
The sixth patent, US 4,947,840, is Prof. Yannas' original patent on tissue
regeneration templates. It was filed in 1987, but received an extension on the patent
term for 923 days past the original expiration date. This means that it still has
approximately a year and a half left of protection. The patent outlines the procedures
for making a scaffold for skin tissue regeneration that is very similar to the currently
proposed scaffold for the liver. The body also contains information on the
composition and purpose of the scaffold that are very close to the liver scaffold.
Since Prof. Yannas is an inventor on the patent, it is unlikely that the patent would
pose difficulties in producing the new liver scaffolds, but the potential for it to raise
"obviousness" concerns by the patent office is quite high if the patent application was
written as broadly as normal.
In summary, it should be possible to attain a patent on the collagen-GAG scaffold by
making certain specifications in the claims that differentiate it from the currently
patented scaffolds. Points of emphasis would likely include the large size of the
scaffold, the targeted organ (liver), and the method by which it induces regeneration
(blocking contraction). The high pore volume fraction and un-banded collagen fibrils
are also important aspects of the scaffold that might strengthen the patent application.
As mentioned above, the manufacturing process of the scaffold, lypholization, is a
very old and known technique and therefore not patentable. Specific alterations to the
process have been patented, but they include steps or materials that are not used in the
production of the collagen-GAG scaffolds for the liver. If VEGF was to be
incorporated into the scaffolds, then the relevant IP would be significantly expanded.
The VEGF itself is sold as a commodity by R&D Systems in Minneapolis, MN. The
PLGA is also sold by various companies, including Sigma Aldrich (St. Louis, MO),
which also supplies the collagen and GAG for the scaffolds. A table depicting the
patentability outlook of the manufacturing methods and device itself for the different
scaffold scenarios is shown below.
Current Form
Manufacturing
VEGF
Microspheres
Scaffold w/
VEGF
Microspheres
Device
+
++
Table 3. Summary of IP outlook with negatives as (-), positives as (+) and unsure areas in gray.
In its current form, collagen-GAG only, the manufacturing process for the scaffold is
unlikely to be patentable since lypholization has been around for many years. If
along the way there were novel alterations to the process then the scenario would
certainly change, but as of now it is not a new process. The device itself is likely to
be patentable in the current form, but it will probably have to be written fairly narrow
due to existing prior art containing collagen-GAG scaffolds. The VEGF
microspheres themselves are currently already patented, so there is obviously no way
of getting a new patent on that. It is marked as gray because of the possibility of
creating a new way to synthesize the microspheres, which could potentially be
patentable. Manufacturing the scaffold with VEGF microspheres is a gray area, the
first patent does teach incorporation of microspheres into a scaffold, but not with
much specificity. It is also likely that the patent office may consider combining a
scaffold with existing microspheres an obvious combination of manufacturing
methods. A scaffold with VEGF microspheres, however, is probably quite patentable
since most existing patents concerning collagen-GAG scaffolds do not include
microspheres, particularly not with VEGF and intended for the liver. This would add
novelty to the invention and make it easier to patent.
Chapter 10. Cost Model
To build an appropriate cost model, it first was necessary to determine the market size
and estimated production numbers. As mentioned in the introduction, there are
multiple causes for liver cirrhosis. Alcoholism is responsible for about 11,000 (40%)
of the more than 27,000 deaths each year. Alcohol induced cirrhosis is likely the
most feasible type to be treated with the collagen-GAG scaffold since its progression
is typically halted once alcohol consumption stops. This means that if the scaffold is
successful in regenerating healthy liver tissue, the treatment will be a success.
Treating patients with hepatitis induced cirrhosis with the liver scaffold may be
successful in the short term, but without treating the underlying disease the
regenerated tissue may just become cirrhotic once again. For these reasons, the target
market has been chosen as roughly double the number of alcohol related cirrhosis
deaths per year, or 20,000 procedures.
It is difficult to attain incidence data (number of diagnoses per year) for alcoholic
cirrhosis since it takes many years to develop and there is no clear-cut line when
fibrosis turns to cirrhosis. However, with the estimated 2 million people that will
develop cirrhosis due to drinking over the next 10-15 years, it would be reasonable to
estimate that an additional 9,000 people will be in the near death stages of cirrhosis in
addition to the 11,000 a year that do die from it. It has been shown that a healthy
liver can regrow from an 85% resection, meaning that 15% is the critical limit for
sustained life (7). Since each scaffold is 3.2% of the total liver volume, five scaffolds
would be required per procedure to reach this critical size. It may be possible that
more or less would be used per procedure based on the determined need, but an
average of five scaffolds per procedure will be used in the cost model. At 20,000
procedures a year and five scaffolds per procedure, 100,000 scaffolds would be
needed per year. For a slightly longer-term outlook, a five year (post FDA approval)
model will be constructed, requiring 500,000 scaffolds. The assumed number of
workdays in a year is 240, allowing for weekends, holidays, and two weeks of
vacation.
The associated costs can be broken down into two overall categories, fixed and
variable. Fixed costs are those that do not change based on the number of scaffolds
produced, for example, lab equipment. Variable costs are those that scale with the
amount of scaffolds produced, and consist predominantly of raw material costs. The
fixed costs can be further broken down into general lab equipment, specific scaffold
production equipment, labor, and FDA trials. The breakdown of the general lab
equipment, scaffold equipment, and labor costs are listed below.
Lab Space Square Feet Price Per sq ft Subtotal
2,000 $30 $60,000
5 Year Total $300000
General Lab Equipment and Supplies Quantity Price per Unit Subtotal
Refridgerators/Freezers 6 $7,000 $42,000
Centrifuge 3 $7,000 $21,000
Analytical Balances 2 $9,500 $19,000
General Lab Equipment 4 $2,500 $10,000
Autoclave 2 $7,000 $14,000
Deionized Water System 1 $22,000 $22,000
Chemical Fume Hoods 4 $6,000 $24,000
Chemical Storage 4 $2,000 $8,000
Total $160,000
Table 4. Cost breakdown for general lab equipment and supplies.
Scaffold Fabrication Equipment Quantity Price per Unit Subtotal
Collagen Suspension Blending Equip. 3 $8,000 $24,000
Freeze Dryer 1 $120,000 $120,000
Vacuum Oven 7 $9,300 $65,100
Desiccators 14 $350 $4,900
total $214,000
Total Lab Equipment Cost $374,000
Table 5. Cost breakdown for scaffold production equipment.
Labor Quantity Cost per Year Years Subtotal
Technician 3 $50,000 5 $750,000
Total $750,000
Table 6. Cost of labor for 5 years.
The general lab equipment and scaffold fabrication equipment costs were calculated
on the basis of 100,000 scaffolds being produced a year (240 work days). The
bottleneck of the production is the freeze-drying process, since it is both time and
capital intensive. As detailed in the manufacturing section, the entire freeze-drying
process takes approximately one day. After freeze-drying, the scaffolds are
crosslinked for a full 24 hours as well. This means that it takes two full days of
preparation to produce each batch of scaffolds. In order to meet the goal of 100,000
scaffolds per year, the freeze-dryer capacity must be able to accommodate about 850
scaffolds per batch. There also must be enough vacuum ovens to handle that many
scaffolds after they come out of the freeze-dryer.
The presence of scrap materials must also be accounted for in these calculations.
Because the scaffolds are created in sheets with a thickness equal to the scaffold
thickness, only two dimensional scrap exists. If the scaffolds are circles stamped out
of a rectangular sheet, then they can be modeled as a simple cubic arrangement. This
is not the most efficient way, but is likely a good approximation for the actual
efficiency that could be expected. Using this model, each sheet would have a yield of
78.5%, meaning that 21.5% of the area is wasted. The freeze-dryer that met this
requirement is the VirTis Ultra Freeze Dryer, with 20.5 x 10.75 inch shelves that can
be adjusted to fit different height clearances.
In order to transfer an entire batch of scaffolds from the freeze-dryer, seven vacuum
ovens are necessary due to their substantially smaller interior volume. The vacuum
oven model chosen was the Fisher Isotemp #282A. It is estimated that three skilled
lab technicians would be necessary to prepare the scaffold suspension as well as
troubleshoot any problems that may occur. Since each batch takes a day in the
freeze-dryer, there would be considerable time during the day for the techs to mix the
suspension for the next day. However, due to the small volumes and specificity of
the ingredients necessary, it is likely that small amounts of suspension will be created
at a time to maintain quality. This means that although the volume might indicate
only one tech would be necessary, the exactness of the process necessitates more.
Preclinical and clinical FDA trials are difficult to build ground-up or top-down cost
models for due to the large variability in the necessary tests for each device, number
of patients needed to prove efficacy, the cost of doing trials in different locations,
and the cost of doing surgical procedures and hospital costs for human patients to
name a few reasons. Preclinical tests are a bit more standardized and a quote from
Pacific BioLabs, a CRO, was received that outlined the costs per test, totaling about
$165,000. The breakdown is given in the table below.
NO. OF PBLTEST TEST: SAMPLE TURNAROUND GLP
TESTS CODE REQUIREMENT TEST NAME AMOUNT (IN WEEKS) UNIT PRICE
1 6521 Cytotoxicity ISO MEM Elutionf 60 cm x 2 3 $415.00
ISO Haximization Test
1 7503 Sensitization (Saline & Vegetable Oil) 60 c x 6 58 ,245.00
1-lurine Local Lymph Node Assay1 7512 Sensitization 6 Em x4 5 - 6 $7,280.00
(Saline & Acetone/Oiive Oil)
ISo Intracutaneous..1 7925 Irritation (Sin & Vegetble ) 60 cn- 2 4 - $780.00
Systemic Iso Acute Systemic Toxicity 775
7231 Toxicity (Saline & Vegetable Oil) 60 cm x 2 4 - 5
1 7200 Systemic Pyrogenicityo 540 cm2  3 - 4 $910.00Toxicity (material mediated)
Subchronic 14 Day Subchronic Toxicity Study
7259 Toxicity ouse I (I 60 cm x 28 piecesC 12 - 14 $88,081.00
-",.e ____,___ tuC st.mu y f e.. : ,d) ig -
1 7934 Implantation ISO Implantation 12 strips 18 - 20 $5,000.00(Subchronic) (90 Days) w/Histopathoiogy 1 x I x 10 mm
Implantation Iso Implantation 12 strips months $7,100.00
1 7935 (Subchronic) (180 Days) w/Histopathology 1 x 1 x 10 mm
1 7931 Implantation ISO Implantation (14 Days) 15 strips - 12,900.00(Subacute) w/Histopathology x 1 x 10 mm2,900.00
1 7936 Implantation ISO Implantation (365 Days) 15 strips 15 months 13,970.00
i 73 (chronic) wjHistopathology 1 x 1 x 10 nin ,
1 Subton- Genotoxidty Ames Test "
tracted Genotoxicity (Saline DMSO) 60 cm x 2 8 - 9 3,040.00
1 Sukon Geno d MHouse Lyrvphoma Forwardu1 - enotoxicity 6 npoa od SO cm' x 2 15 - 17 $10,835.00tracted oxcty Milutation Assay (Saline & DISO) 15-17 10,835.00
Subc- Choromosomal AberrationSu1 tactn- Genotoxicity (2 extracts) 60 cm x 2 12 - 14 $15,180.00tra(td (2 extracts)
Table 7. Costs ofbiocompatibility tests done by Pacific BioLabs (44).
The cost of clinical trials is much more variable, because the number of patients
necessary to prove efficacy changes based on the expected effectiveness of the
treatment. Some studies have only a dozen or two patients, others can have hundreds.
If the scaffold does well in animal models before human testing, the expected
difference between a scaffold-treated patient and a negative control should be quite
high. Therefore, and abundance of patients should not be required to see a statistically
significant improvement. Average costs of clinical trials in the literature range from
$1.5 million to more than $5million in the literature (45, 46, 47). A rough quote,
based on the limited knowledge of the trial size and design, was given by Regulatory
& Clinical Research Institute, another CRO, of $2.5 million. This did not include
some physician and hospital fees. Based on the estimated quote and the average costs
of trials in the literature, a cost of $3 million was assumed for the human clinical
trials. A summary of the preclinical and clinical trial costs are listed below.
FDA Trials
Pre-Clinical $165,000
Clinical $3,000,000
Total $3,165,000
Table 8. Estimated costs of preclinical and clinical trials for FDA approval (44, 48).
The variable costs, or the raw materials costs, make up the vast majority of the overall
cost per scaffold. Collagen from rat tails costs $4.13 per mg and there are about 300
mg of collagen used per scaffold (including scrap). The GAG and acetic acid are
extremely cheap relative to the collagen and add a negligible amount to the cost. If
VEGF microspheres were added to the scaffolds then the cost would rise
dramatically. VEGF purchased from R&D Systems costs $18,100 per mg and 0.225
mg are used per scaffold. The PLGA used to make the microspheres is considerably
cheaper than the VEGF, at $0.034 per mg, but 12 grams are used per scaffold. The
full cost breakdown of the raw materials per scaffold is given below.
Amount per Scaffold Price per mg orRaw Materials Cost per Scaffold(mg or mil) ml
Collagen $301.80 $4.1 $1,237.38
GAG $30.20 $0.023 $0.69
0.05M Acetic Acid $60.40 $0.00145 $0.09
PLGA $12,000 $0.0341 $409.20
VEGF $0.225 $18100 $4,072.50
Table 9. Cost per scaffold for each of the raw materials (49, 50).
With or without VEGF, the raw material costs dominate the cost per scaffold due to
the fairly low equipment costs and high production volumes. The breakdown of the
total cost to produce one scaffold is given below.
% wl/out % w/
Cost Type Total Per Scaffold
VEGF VEGF
Fixed - Lab Costs $674,000 $1.35 0.11 0.02
Fixed - Other $3,915,000 $7.83 0.63 0.14
Variable - Raw Materials $619,080,939 $1,238.16 99.26
w/out VEGF
Variable - Raw Materials w/ $2,859,930,939 $5,719.86 99.84
VEGF
Total w/out VEGF $623,669,939 $1247.34
Total w/ VEGF $2,864,519,939 $5729.04
Table 10. Breakdown of where the costs per scaffold come from.
Chapter 11. Business Model and Supply Chain
The start-up company built around the collagen-GAG scaffold technology will be a
product/manufacturing company. Good quality raw materials (collagen, GAG, etc.) are
readily available in mass quantities so it would not be necessary or cost effective to
produce them within the company. The materials can be purchased and the described
manufacturing steps will be performed to create a finished product. The preclinical and
clinical trials are not really part of the supply chain once they are completed, but during
the early timeline they can be considered a horizontal part of the chain alongside the
manufacturing of the scaffolds. After the scaffolds are created, they will be sold to
hospitals on a semi-need basis. Hospitals prefer not to keep extra devices in their
inventory due to lack of space and adequate storage facilities. Most storage of completed
devices will therefore take place at the company's facility within desiccators that have a
controlled atmosphere to prevent oxidation and other contamination. When the hospitals
schedule a scaffold procedure, they will order the appropriate number of scaffolds. The
patient and/or the patient's insurance will pay for the hospital fees and the scaffolds price
for the implantation procedure. The supply chain therefore looks like this:
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Figure 25. Supply chain for the commercialization of collagen-GAG scaffolds (44, 48, 49, 50, 51, 52).
For a new product to come in and successfully disrupt the current supply chain, in this
case an organ transplant, it must be able to extract value for itself but not alienate the
other members of the chain on which it depends. In this case, the procedural costs far
outweigh the costs of the scaffold and are normally paid by the patient's insurance
company. Insurance companies already do battle with patients on a day-to-day basis
about how much they are willing to pay for many procedures. It is therefore unlikely that
insurance companies will be willing to pay a total amount for the new procedures that is
more than the total amount they are paying now for organ transplants, at least in the short
term before the procedure becomes mainstream and costs are reduced.
To determine the price that can be charged per scaffold it is necessary to find the break-
even point between the total cost of 6500 transplants per year for five years and 20,000
scaffold procedures a year for five years. As previously shown, liver transplants are
extremely expensive. About half of the total cost comes from transplant-specific
procedures or drugs and therefore would be eliminated with the scaffold procedure. In
addition to these reductions, the cost of the hospital stay and testing (the largest single
cost of the transplant) would be drastically reduced due to shorter recovery and follow-up
time. Hospital stays can last for weeks following a transplant. However, it is
conceivable that it would be only a matter of days for a scaffold, since once the surgical
wound is closed the rest of the recovery occurs over time and should not require any
active interference. For this reason, it has been assumed that the remaining costs
associated with the transplant would be cut roughly in half. The costs of the transplant
procedure and the estimated costs of the scaffold procedure are given below.
Follow- IS Drugs
Evaluation Procurement Hospital Physician Total
up (first year)
Liver $25,900 $59,100 $248,100 $66,900 $88,500 $31,100 $519,600
Transplant +
~$360,000 $879,600
For 20 After 20
additional years
years
Liver- $59,100 $31,100 $90,200
specific +
costs ~ $360,000 $450,200
for 20 After 20
additional years
years
Scaffold
Procedure $12,950 $124,050 $66,900 $44,250 $248,150
osts
Table 11. Estimated cost comparison between transplant and scaffold procedure.
According to this estimate, the procedure for implanting the new scaffolds would cost
slightly under $250,000, or 72% less than the cost of a lifelong transplant patient. If the
insurance companies were unwilling to spend a single dollar more than what they do
now, then the price that could be charged per procedure would be the difference between
the total cost of 6,500 transplants a year for five years and doing 20,000 scaffold
procedures a year for five years using the estimated cost divided by the number of
procedures (100,000). This would work out to be approximately $28.6 billion minus
$24.8 billion divided by 100,000, which equals $37,500 per procedure. If five scaffolds
were used for an average procedure, that means a price of $7,500 could be charged per
scaffold. When compared to the cost per scaffold calculated in the cost model, there is an
extremely high profit margin for the non-VEGF scaffold (-500%) and a very good
margin still for the VEGF scaffold (-31%). This means that there is room for some
fluctuation in the price, while still making a profit, of the scaffolds if the number of
procedures changes from the estimated 20,000 per year.
The timeline for starting a company to produce the collagen-GAG scaffolds is shown
below. The yellow portion represents the time still needed in the university setting.
During this time NSF/NIH funds will be used to continue the current mouse research and
expand into cirrhotic mouse livers and possible other animal models. Once that phase is
complete, after about a year and a half, a company will be formed and a lab will be set up
off-campus as detailed in the cost model. During this time samples will be sent to a
CRO, such as Pacific BioLabs, to begin the preclinical trials. The cost of the lab and
preclinical trials are under a million dollars, which means that it is possible that the Small
Business Innovation Research (SBIR) program is a potential source of funding while
waiting for the technology to mature (53). After the preclinical trials are complete and
the lab/manufacturing site is set up, venture capital will be needed to cover the high
initial costs of clinical trials and raw materials for mass production. Approximately $35
million would be required to pay for clinical trials and stock three months of the
necessary raw materials (assuming non-VEGF scaffolds).
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Figure 26. Projected timeline for product development and funding (47).
Chapter 12. Conclusion
The market for a solution to liver cirrhosis is very large, lucrative, and there for the taking
if the right technology can be developed. Transplants cost almost a million dollars over
the course of a patient's lifetime and hospitals, patients, and insurance companies would
all like to see a better, less costly solution. Scaffolds made from collagen and
glycosaminoglycan may be that solution. The scaffolds have been shown to prevent
contraction, the root cause of scar formation, in healthy mice livers and show promise of
being able to regenerate cirrhotic tissue. Numerous technical hurdles lie ahead, the
largest of which is adequate blood vessel ingrowth, or angiogenesis. If these challenges
can be overcome, then high margins are attainable in the marketplace with a product
adoption of slightly less than double the current death rate due to alcohol induced
cirrhosis. The technology is still at least five years from commercialization, possibly up
to ten. The current estimate is that development will require at least another year and a
half in the university before moving on to a small-scale manufacturing lab funded by the
SBIR. After that, venture capital will be needed to pay for the high cost of FDA trials
and raw materials. Overall, the company should be able to create a successful product
that makes a profit while it simultaneously lowers individual patient medical costs,
maintains current costs for insurance companies, and most importantly, helps to reduce
hospital stays and save lives.
References
1. National Center for Health Statistics. "Chronic Liver Disease/Cirrhosis."
http://www.cdc.gov/nchs/FASTATS/liverdis.htm
2. American Liver Foundation. "Cirrhosis."
http://www.liverfoundation.org/education/info/cirrhosis
3. Substance Abuse and Mental Health Services Administration. "Alcohol."
http://ncadistore.samhsa.gov/catalog/facts.aspx?topic=3
4. "Liver Functions." http://www.hepar-p.com.my/liverfunctions.htm
5. "Hepatitis B: Patient Education."
http://www.stanford.edu/group/virus/hepadna/2004tansilvis/Patient%2OEd.htm
6. Martini F.H., Timmons M.J. Human Anatomy. San Francisco: Pearson, 2006.
7. Snell R.S. Clinical Anatomy by Systems. Baltimore: Lippincott, 2007.
8. "Descriptive Liver Anatomy." http://www.uni-bonn.de/-umm705/quiz0403.htm
9. "Digestive System."
http://www.mc.vanderbilt.edu/histology/labmanual2002/labsection3/PancreasLive
rGallbladder03.htm
10. Mayo Clinic. "Liver transplant: Treating end-stage liver disease."
http://www.mayoclinic.com/health/liver-transplant/DG00037
11. Hauboldt R.H. "2007 U.S. organ and tissue transplant cost estimates." Milliman
consulting firm, 2007.
12. California Pacific Medical Center. "Financial Matters: Liver Transplant Costs."
http://www.cpmc.org/advanced/liver/patients/topics/finance.html
13. Jin B., Alter H.J., et al. "Reversibility of experimental rabbit liver cirrhosis by
portal collagenase administration," Laboratory Investigation, 85: 992-1002
(2005).
14. Vinokurov A.P., et al., "Dobutamine Prevents Experimental Postintoxication
Liver Cirrhosis in Mice," Bulletin of Experimental Biology and Medicine 134(1):
43-46 (2002).
15. Buck M., Chojkier M., "A Ribosomal S-6 Kinase-Mediated Signal to C/EBP-3 is
Critical for the Development of Liver Fibrosis," PLoS ONE, 2(12): e1372 (2007).
16. Kadler K.E., et al., "Collagens at a glance," Journal of Cell Science 120: 1955-
1958 (2007).
17. Lodish H., et al. Molecular Cell Biology. New York: W.H. Freeman, 2000.
18. "About Collagen."
http://www.kokenmpc.co.jp/english/support/tecnical/collagen/index.html
19. Zern M.A., Reid L.M. Extracellular Matrix: Chemistry, Biology, and
Pathobiology with Emphasis on the Liver. New York: Marcel Dekker, 1993.
20. Jackson R.L., et al. "Glycosaminoglycans: Molecular Properties, Protein
Interactions, and Role in Physiological Processes," Physiological Reviews, 71(2)
1991.
21. Yannas I.V., et al. "Influence of freezing rate on pore structure in freeze-dried
collagen-GAG scaffolds," Biomaterials 25: 1077-1086 (2004).
22. Rhim J.A., et al. "Complete reconstitution of mouse liver with xenogeneic
hepatocytes," Proc. Natl. Acad. Sci. 92: 4942-4946 (1995).
23. Leach K.G., et al. "In vivo assessment of liver size in the rat," Journal of Nuclear
Medicine, 16(5): 380-385 (1974).
24. Andersen V., et al. "The volume of the liver in patients corresponds to body
weight and alcohol consumption," Alcohol and Alcoholism, 35(5): 531-532
(2000).
25. Spector M, Yannas I.V. Biomaterials: Tissue Interactions, MIT Lecture Notes,
2007.
26. Harley B.A., "Mechanical characterization of collagen-glycosaminoglycan
scaffolds." Acta Biomaterialia, 3: 463-474 (2007).
27. "Phase diagram for water."
http://www.earth.northwestem.edu/people/seth/202/new_2004/H2Ophase.html
28. Yannas I.V., et al. "The effect of pore size on cell adhesion in collagen-GAG
scaffolds," Biomaterials, 26: 433-441 (2005).
29. "Lap Equipment and Supplies." www.daigger.com
30. "Pilot Lyophlizers." www.virtis.com
31. "Artisan Scientific." www.artisan-scientific.com
32. Yannas I.V., et al. "Design of an artificial skin. II. Control of chemical
composition," J. Biomed. Mater. Res., 14: 107-131 (1980).
33. Dunn J.C.Y., et al. "Analysis of Cell Growth in Three-Dimensional Scaffolds,"
Tissue Engineering, 12(4): 705-716 (2006).
34. Ko H.C.H., et al. "Engineering thick tissues - the vascularization problem,"
European Cells and Materials, 14:1-19 (2007).
35. Yan Y., et al. "Fabrication of viable tissue-engineered constructs with 3D cell-
assembly technique," Biomaterials, 26: 5864-5871 (2005).
36. Landman K.A., Cai A.Q., "Cell Proliferation and Oxygen Diffusion in a
Vascularising Scaffold," Bulletin of Mathematical Biology, 69: 2405-2428 (2007).
37. Yannas I.V., Burke J.F., "Design of an artificial skin. I. Basic design principles,"
J. Biomed. Mater. Res., 14: 65-81 (1980).
38. Kedem A., et al. "Vascular Endothelial Growth Factor-Releasing Scaffolds
Enhance Vascularization and Engraftment of Hepatocytes Transplanted on Liver
Lobes," Tissue Engineering, 11(5/6): 715-722 (2005).
39. Chen L., "Characterization of PLGA microspheres for the controlled delivery of
IL-la for tumor immunotherapy," J. Control. Release, 43: 261-272 (1997).
40. O'Brien F.J., "The effect of pore size on permeability and cell attachment in
collagen scaffolds for tissue engineering," Technology and Health Care, 15: 3-17
(2007).
41. Mian R., et al., "Formation of New Tissue from an Arteriovenous Loop in the
Absence of Added Extracellular Matrix," Tissue Engineering, 6(6): 595-603
(2000).
42. www.fda.gov
43. FDA PMA# P000058 Summary of Safety and Effectiveness Data, "InFUSE Bone
Graft/LT-CAGE Lumbar Tapered Fusion Device," 2002.
http://www.fda.gov/cdrh/pdf/P000058b.pdf
44. Pacific BioLabs, "Quotation for Testing Services," 2008.
45. Stark N.J., "The Clinical Research Industry: New Options for Medical Device
Manufacturers," Medical Device Link (1997).
46. Medical Metrics, Inc. "FDA Guidance," (2006).
http://www.medicalmetrics.com/fda.htm
47. Lysaght M.J., "Product Development in Tissue Engineering," Tissue Engineering,
1(2): 221-228 (1995).
48. Regulatory & Clinical Research Institute, Inc. (2008). http://www.rcri-inc.com/
49. Sigma-Aldrich (2008).
http://www.sigmaaldrich.com/Area_of_Interest/The_Americas/United_States.htm
I
50. R&D Systems (2005). http://www.mdsystems.com/
51. "Chelsea and Westminster Hospital."
http://www.chelwest.nhs.uk/services/womenchildren/maternity/virtual tour/labou
r/2.html
52. "Home Bound Resources."
http://www.homeboundresources.com/testimonials.html
53. Fitzgerald E.A. Technology Development and Evaluation, MIT Lecture Notes,
2008.
